<DOC>
	<DOC>NCT02846961</DOC>
	<brief_summary>The purpose of this study is to evaluate the development of anti-drug antibody to biosimilar CT-P13 and to assess the change of drug concentration for 1 year in patients with moderately to severe inflammatory bowel disease.</brief_summary>
	<brief_title>Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Clinical diagnosis of Crohn's disease or ulcerative colitis Tuberculosis infection Allergy to CTP13</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>biosimilar</keyword>
	<keyword>anti-drug antibody</keyword>
	<keyword>trough drug concentration</keyword>
</DOC>